| JPM THEMATICS-GENETIC THERAPIES C (DIST) USD | RVI BIOTECNOLOGÍA | 39,63% | 24,23% | -23,26% | · |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 36,19% | 24,10% | -33,43% | · |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) USD | RVI BIOTECNOLOGÍA | 38,25% | 19,94% | -28,01% | · |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 38,36% | 30,01% | -28,16% | · |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) USD | RVI BIOTECNOLOGÍA | 40,49% | 25,82% | -22,08% | · |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 40,97% | 25,84% | -22,51% | · |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 38,22% | 29,65% | -28,46% | · |
| JPM TOTAL EMERGING MARKETS INCOME A (DIV) EUR | MIXTO AGRESIVO GLOBAL | 17,01% | 21,22% | 4,99% | · |
| JPM TOTAL EMERGING MARKETS INCOME I2 (ACC) EUR | MIXTO AGRESIVO GLOBAL | 24,89% | · | · | · |
| JPM TOTAL EMERGING MARKETS INCOME I2 (ACC) EUR (HEDGED) | MIXTO AGRESIVO GLOBAL | 21,04% | 49,87% | 26,09% | · |
